NasdaqGS:AMGNBiotechs
How Amgen’s DISCO Oncology Licensing Deal Will Impact Amgen (AMGN) Investors
Earlier this month, DISCO Pharmaceuticals announced an exclusive license agreement granting Amgen global rights to develop and commercialize cancer therapies from DISCO’s cell-surface proteomics platform, with DISCO eligible for up to US$618 million in total deal value plus royalties.
This partnership adds another specialized oncology program to Amgen’s pipeline at the same time that investors are closely watching its late-stage obesity and cardiovascular candidates.
We’ll now examine how...